Poudre Valley Health Care, INC
Poudre Valley Health Care, INC was paid $3.86M by Medicaid between Jan 2018 and Dec 2024, across 19 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
FORT COLLINS, CO 80524
Next to other Clinic/Center providers in Colorado
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,843 | $595K | |
| 2019 | 11,665 | $689K | |
| 2020 | 6,640 | $436K | |
| 2021 | 8,655 | $452K | |
| 2022 | 10,704 | $667K | |
| 2023 | 10,222 | $707K | |
| 2024incomplete | 5,455 | $320K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 22,108 | 20,866 | $1.29M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 14,968 | 14,043 | $1.26M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 13% | 3,741 | 3,552 | $518K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 5,153 | 4,839 | $444K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.0% | 6,885 | 6,462 | $233K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 454 | 404 | $37K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 658 | 641 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,370 | 1,320 | $19K |
| 81025 | <1% | 2,259 | 2,145 | $17K | |
| 81003 | <1% | 4,927 | 4,660 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 35 | 32 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 288 | 249 | $4K |
7 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 161 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18 | $820.96 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30 | $547.47 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 39 | $539.49 |
| 90686 | <1% | 17 | $269.55 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 52 | $6.65 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 21 | $2.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.